BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23435401)

  • 1. Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers.
    Okafor PN; Wasan SK; Farraye FA
    Inflamm Bowel Dis; 2013; 19(4):812-7. PubMed ID: 23435401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?
    Okafor PN; Nunes DP; Farraye FA
    Inflamm Bowel Dis; 2013 Jul; 19(8):1764-71. PubMed ID: 23615530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of Pneumocystis jirovecii prophylaxis use among pediatric solid organ transplant providers.
    Paulsen G; Michaels MG; Danziger-Isakov L; Dipchand AI; Green M; McCulloch M
    Pediatr Transplant; 2020 Feb; 24(1):e13609. PubMed ID: 31713958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
    Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
    Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.
    Sierra CM; Daiya KC
    Pharmacotherapy; 2022 Nov; 42(11):858-867. PubMed ID: 36222368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
    Liebling M; Rubio E; Ie S
    Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of Pneumocystis jirovecii pneumonia in Korean patients with inflammatory bowel disease.
    Nam K; Park SH; Lee J; Jo S; Kim SO; Noh S; Park JC; Kim JY; Kim J; Ham NS; Oh EH; Song EM; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK
    J Gastroenterol Hepatol; 2020 Feb; 35(2):218-224. PubMed ID: 31412420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
    Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
    Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
    Gupta D; Zachariah A; Roppelt H; Patel AM; Gruber BL
    J Clin Rheumatol; 2008 Oct; 14(5):267-72. PubMed ID: 18679133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review.
    Grewal P; Brassard A
    J Cutan Med Surg; 2009; 13(6):308-12. PubMed ID: 19919808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease-a Case Series.
    Vieujean S; Moens A; Hassid D; Rothfuss K; Savarino EV; Vavricka SR; Reenaers C; Jacobsen BA; Allez M; Ferrante M; Rahier JF
    J Crohns Colitis; 2023 Apr; 17(4):472-479. PubMed ID: 36223253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States.
    Tinsley A; Naymagon S; Trindade AJ; Sachar DB; Sands BE; Ullman TA
    J Clin Gastroenterol; 2013 Jan; 47(1):e1-6. PubMed ID: 22476043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis.
    Cettomai D; Gelber AC; Christopher-Stine L
    J Rheumatol; 2010 Apr; 37(4):792-9. PubMed ID: 20194450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
    Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
    Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients.
    Razik R; Bernstein CN; Sam J; Thanabalan R; Nguyen GC
    Can J Gastroenterol; 2012 Nov; 26(11):795-8. PubMed ID: 23166902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practices and attitudes toward complementary and alternative medicine in inflammatory bowel disease: a survey of gastroenterologists.
    Gallinger ZR; Nguyen GC
    J Complement Integr Med; 2014 Dec; 11(4):297-303. PubMed ID: 25294717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.
    Cotter TG; Gathaiya N; Catania J; Loftus EV; Tremaine WJ; Baddour LM; Harmsen WS; Zinsmeister AR; Sandborn WJ; Limper AH; Pardi DS
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):850-856. PubMed ID: 28013116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
    Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
    Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts' Opinion and Systematic Review from the Literature.
    Navarro M; Allemang-Trivalle A; Leducq S; Jonville-Bera AP; Maurier A; Zejli T; Edée AE; Harchaoui E; Giraudeau B; Maruani A
    Dermatology; 2023; 239(6):942-951. PubMed ID: 37793356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors of
    Yoon J; Hong SW; Han KD; Lee SW; Shin CM; Park YS; Kim N; Lee DH; Kim JS; Yoon H
    Gut Liver; 2024 May; 18(3):489-497. PubMed ID: 37867439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.